/PRNewswire/ Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced.
Bolton-St Johns comes to D C politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
Published: May 21, 2021 By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.
(0)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company, and #2 in overall corporate reputation among U.S. patient groups familiar with the company. These results are based on PatientView s annual survey of 207 U.S. patient groups who evaluated 38 pharmaceutical and biotechnology companies. Every day our patient advocacy team is working with patient groups to support their efforts toward improving the lives of people living with some of the most challenging diseases, said Matt Flesch, vice president, patient advocacy and communications, Horizon. To be recognized by these patient groups who we have learned so much from and whose insights have guided nearly every facet of our work is an honor. We are humbled by the feedback provided within the PatientView report and look forward to continued opportunities to support the transformative work led by patient advocacy
(0) In its inaugural year on the survey, Horizon had top rankings in integrity, patient information and services among patient groups partnering with the company
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #4 in overall corporate reputation among nearly 50 pharmaceutical and biotech companies based on PatientView s annual survey of 1,920 patient groups worldwide. We are incredibly grateful to work with patient groups who share our commitment to improving the lives of people living with rare, autoimmune and severe inflammatory diseases, said Tim Walbert, chairman, president and chief executive officer, Horizon. At Horizon, our patient advocacy team works diligently to listen, learn and partner with patient groups in order to incorporate those critical voices and experiences into everything we do. We re humbled by these results and thank all of the patient organizations who shared their perspectives.